用比伐卢定引起严重出血的差异使相对危险度降低33%。
The difference in major bleeding translated into a 33% lower relative risk with bivalirudin.
ACS患者行pci术时使用比伐卢定后1年内对结果的影响仍然未知。
The impact of bivalirudin on 1-year outcomes in ACS patients undergoing PCI is unknown.
他总结道，复合结果在数字上是支持比伐卢定，因为(它)不增加缺血事件却降低严重出血的发生。
He concluded that the composite results were numerically in favor of bivalirudin, with no increase in ischemic events but a marked reduction in major bleeding.
应用推荐